Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR ® Post-Hoc Analysis

Anzueto, Antonio; Calverley, Peter M.A.; Mueller, Achim; Metzdorf, Norbert; Haensel, Michaela; Jardim, José Roberto; Pizzichini, Emílio; Giraldo, Horacio; Ramírez‐Venegas, Alejandra; Giugno, Eduardo

doi:10.1016/j.arbres.2017.11.010

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indudablemente deben establecerse medidas para evitar la exposición a estos agentes causales que incrementan las exacerbaciones de la EPOC, las cuales constituyen el principal factor de riesgo de agravamiento, discapacidad, pérdida de la calidad de vida y letalidad. Es interesante señalar que los pacientes con EPOC en América Latina tienen un mayor riesgo de muerte y exacerbaciones moderadas a graves, que probablemente se asocien a una mayor carga de tabaquismo (30). En el estudio PUMA (Prevalence StUdy and Regular Practice, Diagnosis and TreatMent, Among General Practitioners in Populations at Risk of COPD in Latin America) realizado en Argentina, Colombia, Venezuela y Uruguay, se demostró que los pacientes con antecedente de exposición al humo de biomasa tuvieron una mayor frecuencia de exacerbaciones (31).…”

Section: Discussionunclassified

Incidencia de exacerbación moderada y severa en enfermedad pulmonar obstructiva crónica y factores de riesgo asociados

Velázquez–Ordoñez

Peña

2022

Gac Méd Caracas

View full text Add to dashboard Cite

Introducción: La enfermedad pulmonar obstructiva crónica es una causa frecuente de morbilidad y mortalidad en América Latina y las exacerbaciones incrementan su carga. Objetivo: Medir la incidencia acumulada de exacerbaciones moderadas y graves y los factores de riesgo asociados. Material Métodos: Se realizó un estudio de seguimiento a un año en pacientes con enfermedad pulmonar obstructiva crónica. Las exacerbaciones se evaluaron en el servicio de urgencias. Se midieron variables clínicas relacionadas con la exacerbación. Se estimó la incidencia acumulada con intervalos de confianza al 95 %. Se evaluó la participación independiente de cada factor de riesgo en un modelo multivariado de regresión logística, estimando la razón de momios con intervalos de confianza al 95 %.

show abstract

Section: Discussionunclassified

Incidencia de exacerbación moderada y severa en enfermedad pulmonar obstructiva crónica y factores de riesgo asociados

Velázquez–Ordoñez

Peña

2022

Gac Méd Caracas

View full text Add to dashboard Cite

show abstract

“…In patients with a history of cardiac arrhythmia, tiotropium Respi-mat® 2.5 μg and tiotropium HandiHaler®18 μg had a similar impact on survival as measured by all-cause mortality. In addition to these analyses, various post hoc analyses were conducted to assess the impact of geographical variations [82] on COPD outcomes, to evaluate spirometry outcomes [83], and to determine risk factors for exacerbations [84]. Tiotropium Respimat® 5 μg was associated with a similar improvement in trough FVC and a comparable rate of decline in FEV 1 as tiotropium HandiHaler® 18 μg in the spirometry outcomes analysis [83].…”

Section: Landmark Safety Trialmentioning

confidence: 99%

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development

Anzueto

Miravitlles

2020

Respir Res

Self Cite

View full text Add to dashboard Cite

Background: Bronchodilators are the mainstay of pharmacological treatment in chronic obstructive pulmonary disease (COPD), and long-acting muscarinic antagonist (LAMA) monotherapy is recommended as initial treatment for Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups B, C, and D. Main body: Tiotropium bromide was the first LAMA available for COPD in clinical practice and, because of its long duration of action, is administered once daily. Tiotropium was initially available as an inhalation powder delivered via a dry-powder inhaler (DPI). Later, tiotropium also became available as an inhalation spray delivered via a soft mist inhaler (SMI). The SMI was designed to overcome or minimize some of the issues associated with other inhaler types (eg, the need for strong inspiratory airflow with DPIs). Results of short-and long-term randomized, controlled clinical trials of tiotropium in patients with COPD indicated tiotropium was safe and significantly improved lung function, health-related quality of life, and exercise endurance, and reduced dyspnea, lung hyperinflation, exacerbations, and use of rescue medication compared with placebo or active comparators. These positive efficacy findings triggered the evaluation of tiotropium in fixed-dose combination with olodaterol (a long-acting β 2-agonist). In this review, we provide an overview of studies of tiotropium for the treatment of COPD, with a focus on pivotal studies. Conclusion: Tiotropium is safe and efficacious as a long-term, once-daily LAMA for the maintenance treatment of COPD and for reducing COPD exacerbations. The SMI generates a low-velocity, long-duration aerosol spray with a high fine-particle fraction, which results in marked lung drug deposition. In addition, high inspiratory flow rates are not required.

show abstract

Phenotyping COPD

Lόpez-Campos¹

2020

Precision Medicine for Investigators, Practitioners and Providers

View full text Add to dashboard Cite

Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR ® Post-Hoc Analysis

Cited by 5 publications

References 21 publications

Incidencia de exacerbación moderada y severa en enfermedad pulmonar obstructiva crónica y factores de riesgo asociados

Incidencia de exacerbación moderada y severa en enfermedad pulmonar obstructiva crónica y factores de riesgo asociados

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development

Phenotyping COPD

Contact Info

Product

Resources

About